Log in to save to my catalogue

2207

2207

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ac0a3f3ef62d4299b51e5e38ce39e840

Publication information

Publisher

Cambridge University Press

More information

Scope and Contents

Contents

OBJECTIVES/SPECIFIC AIMS: Patients with locally advanced pancreatic cancer typically have poor outcomes, with a median survival of ~16 months. Novel methods to improve local control are needed. Nab-paclitaxel (abraxane) has shown efficacy in pancreatic cancer and is FDA approved for metastatic disease in combination with gemcitabine. Nab-paclitaxel...

Alternative Titles

Full title

2207

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ac0a3f3ef62d4299b51e5e38ce39e840

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ac0a3f3ef62d4299b51e5e38ce39e840

Other Identifiers

E-ISSN

2059-8661

DOI

10.1017/cts.2017.121

How to access this item